NGeneBio Co

NGeneBio Co Current Assets

The Current Assets of NGeneBio Co (354200.KQ) as of Nov 19, 2026 is 1.42 B KRW. In the previous year, Current Assets was 11.57 B KRW — a change of -87.70% (lower).

Current Assets

1.42 BKRW

YoY

-87.70%

Last updated:

Current Assets of NGeneBio Co is 2025 1.42 B KRW. Current Assets of NGeneBio Co was 2024 11.57 B KRW. It decreases by -87.70% lower compared to the previous year.

The NGeneBio Co Current Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Current Assets
Date
Current Assets
Jan 1, 2018
8.89 B KRW
Jan 1, 2019
6.85 B KRW
Jan 1, 2020
42.23 B KRW
Jan 1, 2021
27.25 B KRW
Jan 1, 2022
43.04 B KRW
Jan 1, 2023
25.17 B KRW
Jan 1, 2024
11.57 B KRW
Jan 1, 2025
1.42 B KRW
The NGeneBio Co Current Assets history
YEARCurrent AssetsYoY
1.42 BKRW-87.70%
11.57 BKRW-54.04%
25.17 BKRW-41.52%
43.04 BKRW+57.95%
27.25 BKRW-35.48%
42.23 BKRW+516.89%
6.85 BKRW-23.02%
8.89 BKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

NGeneBio Co Stock analysis

What does NGeneBio Co do? NGeneBio Co., Ltd. generates revenue through the development and sale of diagnostic products for cancer-related genetic testing. The company offers BRCAaccuTest for hereditary breast and ovarian cancer, HEMEaccuTest for blood cancer gene testing including leukemia and lymphoma, and SOLIDaccuTest for solid cancer tissues like lung and colon cancer. Additional products include HLAaccuTest for bone marrow transplantation antigen testing, ONCOaccuPanel for large-capacity solid cancer diagnosis, and HEREDaccuTest for rare disease diagnosis. The firm also provides direct-to-consumer genetic testing and personalized healthcare services, targeting healthcare providers, hospitals, and individual consumers seeking genetic insights. The company's product portfolio serves medical institutions and patients requiring precise genetic diagnostics. HEMEaccuTest specifically addresses blood cancer types such as leukemia and lymphoma, while SOLIDaccuTest covers common solid cancers including lung and stomach cancer. ONCOaccuPanel supports comprehensive solid cancer diagnosis, and HEREDaccuTest caters to rare disease diagnostics. These products are sold to healthcare facilities and offered directly to consumers through DTC services. NGeneBio's revenue streams include sales of diagnostic kits and services, with a focus on cancer-related genetic testing. The BRCAaccuTest, HEMEaccuTest, and SOLIDaccuTest products are central to its business, targeting both clinical and direct consumer markets. Personalized healthcare services complement the product offerings, enhancing customer engagement and recurring revenue opportunities. NGeneBio Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about NGeneBio Co stock

Current Assets of NGeneBio Co is 1.42 B KRW in 2025.

Current Assets of NGeneBio Co changed from 11.57 B KRW to 1.42 B KRW, representing a -87.70% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Current Assets NGeneBio Co since 2006 – with annual values, charts, and detailed analysis.

Current assets are assets expected to be converted to cash within one year, including cash, receivables, and inventory.

Current Assets's KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Assets's NGeneBio Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — NGeneBio Co

All Key Metrics — NGeneBio Co